Furthermore, resistance to therapies has been related to the activation of Nrf2 together with HO-1, as shown by our group in neuroblastoma cells after GSH depletion or bortezomib exposure [90, 91] and by others in cisplatin-treated ovarian carcinoma cells [156] and in doxorubicin-resistant breast cancer cells [86]. Here, HMOX1 is linked to breast cancer.